Tandem Diabetes Care (TNDM) Operating Leases (2019 - 2026)

Tandem Diabetes Care (TNDM) has 8 years of Operating Leases data on file, last reported at $112.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 21.5% year-over-year to $112.9 million; the trailing twelve-month figure through Mar 2026 stood at $112.9 million (down 21.5% YoY), and the FY2025 full-year result was $115.0 million, up 8.03% from the prior year.
• Operating Leases for Q1 2026 stood at $112.9 million, down from $115.0 million in the prior quarter.
• Across five years, Operating Leases topped out at $143.8 million in Q1 2025 and bottomed at $3.0 million in Q2 2022.
• The 5-year median for Operating Leases is $118.4 million (2025), against an average of $113.4 million.
• The widest annual swing landed in 2022, when Operating Leases slumped 91.81%; it then soared 3846.67% in 2023.
• A 5-year view of Operating Leases shows it stood at $123.5 million in 2022, then dropped by 8.06% to $113.6 million in 2023, then slipped by 6.3% to $106.4 million in 2024, then increased by 8.03% to $115.0 million in 2025, then decreased by 1.83% to $112.9 million in 2026.
• The last three Operating Leases figures came in at $112.9 million (Q1 2026), $115.0 million (Q4 2025), and $118.4 million (Q3 2025), per Business Quant data.

Peer Comparison